Navigation Links
Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership

SAN DIEGO, Sept. 21 /PRNewswire/ -- ChemDiv, Inc. (San Diego) announced today that its Chemical Diversity Research Institute (CDRI, Moscow) is undertaking a partnership with the Blokhin Russian Oncology Center (RONC) of the Russian Academy of Medical Sciences, the US Department of Energy (DOE), and the US National Cancer Institute (NCI) to develop novel small molecule therapies for the prevention and treatment of prostate cancer (PRC). The partnership will operate under the auspices of The Global Initiatives for Proliferation Prevention Program.

PRC is the most frequently occurring cancer among males in developed countries and accounts for nine percent of cancer deaths in men, second only to lung cancers. PRC is frequently asymptomatic in the early stages, and later stage diagnosis greatly reduces the efficacy of available therapeutic methods.

This project sets a vivid example of international cooperation between leading Russian and U.S. research centers in medical science research aimed at life threatening diseases. CDRI and its collaborators will deploy post-genome technologies including rational drug design and medicinal chemistry, chemical genomics and systems biology to support efficient preclinical discovery and development programs. The American partners from the Oak Ridge National Laboratory (ORNL, DOE) will provide a knowledge base system for chemical and biological information, using Modular Chemical Descriptor Language technology. Experts from other Russian leading academic research institutions and the NCI will be engaged in the project.

"ChemDiv and CDRI established a long track record of success in lead discovery, with specific expertise in oncology pathway chemistry and biology," said Dmitry Kravchenko, General Director of CDRI. "This opportunity allows us to expand our collaboration with the leading experts in oncology and rational drug design in an especially meaningful context -- targeting a major unmet need for new approached to the prevention and treatment for prostate cancer in United States, Russia, and world wide."

The initial two-year partnership has received financial commitments in excess of US$1,000,000. CDRI and DOE will have joint rights to commercialize products in most of the world, whereas CDRI will have exclusive commercial rights for markets in Russia and certain other countries.

About The Global Initiatives for Proliferation Prevention Program of the U.S. Department of Energy (GIPP/DOE): The mission of The Global Initiatives for Proliferation Prevention program encourages and supports cooperative civilian research between US research teams and researchers from the countries of the former USSR, utilizing their extensive hi-tech and scientific experience. The goals of GIPP-sponsored joint projects are to promote identification and utilization of new scientific and technical resources, and to increase the investment appeal and commercial potential of technologies developed in scientific research institutes of the former Soviet Union.

About CDRI: The Chemical Diversity Research Institute, housed in dedicated world-class research facilities in Moscow, is a leading Russian commercial biotech specialized in advanced combinatorial, medicinal and computational chemistry; and high-throughput screening for early drug discovery.

About ChemDiv: ChemDiv Inc. (Chemical Diversity) is a global chemistry-driven contract research organization focused on identifying and delivering pre-clinical opportunities and services for life science partners, merging industrial and academic efforts to bring new approaches to the treatment of life-threatening diseases.

About Blokhin Russian Oncology Center (RONC): The Russian Oncology Center is the leading oncology research and clinical institution specialized in diagnostics and development of anticancer therapies. The Center provides a comprehensive range of therapies from oncology specialists; and performs clinical research, therapeutic development, and pursues translational onco-medicine.

About NCI: The National Cancer Institute is the world's largest organization solely dedicated to cancer research. NCI supports researchers at universities and hospitals across the United States and at NCIDesignated Cancer Centers, a network of facilities that not only study cancer in laboratories, but conduct research on the best ways to rapidly bring the fruits of scientific discovery to cancer patients. As the leader of the National Cancer Program, NCI provides vision and leadership to the global cancer community, conducting and supporting international research, training, health information dissemination, and other programs.

About Oak Ridge National Laboratory (ORNL/ DOE)

ORNL is a multi-program science and technology laboratory managed for the U.S. Department of Energy by UT-Battelle, LLC. Scientists and engineers at ORNL conduct basic and applied research and development to create scientific knowledge and technological solutions that strengthen America's leadership in key areas of science; increase the availability of clean, abundant energy; restore and protect the environment; and contribute to national security.

SOURCE ChemDiv, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Chemical in Gila monsters saliva yields Alzheimer drug
2. Biochemical Markers Might Help Predict Heart Problems
3. Chemical found in plants may be the treatment for leukemia
4. Chemicals in clear plastics can cause learning difficulties
5. Harmful chemicals change the genetic response to hormone estrogen
6. Quitting Smoking Made Easy By Track Of New Chemical
7. Brain Chemical Identified For Drug Dependent Behavior
8. Toxic chemicals found in domestic products poisoning newborn babies
9. Block Immune System Chemical For Treating Asthma
10. Chest Pain Can Be Identified By New Tracer Chemical 30 Hours After Pain Relief
11. Cancer Causing Proteins Trigger Abnormal Biochemical Reactions In Cells
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today ... Golden Bridge Business Awards under the New Products and Services category for its ... sample management software that helps labs organize data and track samples ...
(Date:12/1/2015)... ... 01, 2015 , ... The workstation boundaries for imaging specialists ... Systems launches MED-TAB™ -- the world’s first portable DICOM-calibrated medical image display, debuting ... December 4, 2015. , MED-TAB is expected to change teleradiology because for ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... of adjunctive imaging is the focus of numerous abstracts accepted for presentation here, ... 4, 2015. Nine abstracts highlight the use of Volpara Solutions’ quantitative breast ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the millions of people ... Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic intermittent catheter. “Hollister ... free catheter portfolio,” said Michael Gresavage, Vice President North America. "We designed our ...
(Date:12/1/2015)... ... 01, 2015 , ... SAN FRANCISCO, Calif. (December 1, 2015) ... has awarded Education and Developmental Therapies (EDT), an Applied Behavior Analysis (ABA) service ... special needs providers that excel in synthesizing the areas of clinical quality, staff ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... WellStar Health System has signed a definitive ... Tenet Healthcare,s five metro Atlanta ... move following the conclusion of the due diligence period. ... and patient safety programs that have resulted in increased ... --> --> With ...
(Date:12/1/2015)... 1, 2015   Nottingham Spirk , a ... the publication of a free whitepaper , ... Market". The whitepaper gives medical product companies, pharmaceutical ... this lucrative segment. Nottingham Spirk ... manage their own health, save money (i.e., fewer ...
(Date:12/1/2015)... WASHINGTON , Dec. 1, 2015 A federal ... motion to dismiss a lawsuit filed by the Pharmaceutical ... Arkansas 900, a new law that forces employers ... Arkansas must now defend ... consumers," said PCMA President and CEO Mark Merritt . ...
Breaking Medicine Technology: